Selection was also based on the presence of Kirsten rat sarcoma virus (KRAS) mutations in all three cell lines, as KRAS mutations are highly prevalent in rectal cancers and we assumed that MEK1/2 inhibition would be more potent in models with activated RAS-MAPK signaling.9 This evidence concerns the gene MAP2K1 and rectal cancer.